ABSTRACT

The incidence of pancreatic cancer is increasing. Most patients have advanced disease at diagnosis, and therapeutics is limited in this setting. Gemcitabine and nab-paclitaxel combination is indicated as first-line treatment in patients with metastatic cancer of pancreas. The most common adverse events of Grade 3 or higher gemcitabine and nab-paclitaxel combination are neutropenia, fatigue and neuropathy. In this report, we describe a rare case of organizing pneumonia associated with the use of nab-paclitaxel and gemcitabine in metastatic pancreatic cancer. A 68-year-old female underwent total splenopancreatectomy for ductal adenocarcinoma of the neck of the pancreas, followed by adjuvant chemoradiation therapy. Afterwards she relapsed and received first-line chemotherapy with gemcitabine plus nab-paclitaxel combination for 12 cycles. Following the administration of the 12th cycle of gemcitabine plus nab-paclitaxel, the patient experienced low-grade pyrexia, effort dyspnoea, persistent non-productive cough and malaise. High-resolution CT scan of chest revealed new-onset bilateral peripheral ground-glass opacities, smooth interlobular septal thickening and patchy subpleural consolidation areas, findings consistent with organizing pneumonia. A thorough microbiological workup was negative. Treatment with steroids resulted in prompt clinical and radiological improvement. Organizing pneumonia closely mimics infection or progressive disease and can be difficult to diagnose in the setting of malignancy. Correct diagnosis is of primary importance since delay in treatment can result in significantly adverse patient outcomes.

Cite this article as: Comito F, Grassi E, Poerio A, Freier E, Calculli L, Zompatori M, et al. Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report. BJR Case Rep 2018; 4: 20170086.

CASE REPORT

Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report

FRANCESCASCOMITO, MD, ELISAGRASSI, MD, ANTONIOPOERIO, MD, EVA FRIER, MD, LUCIA CALCULLI, MD,
MAURIZIO ZOMPATORI, MD, CLAUDIO RICCI, MD, RICCARDO CASADEI, MD, PhD and
MARIACRISTINA DI MARCO, MD, PhD

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Sant’Orsola-Malpighi Hospital, Bologna, Italy
Department of Radiology, Sant’Orsola-Malpighi Hospital, Bologna, Italy
Department of Medical and Surgical Sciences, University of Bologna, Sant’Orsola-Malpighi Hospital, Bologna, Italy

Address correspondence to: Dr Francesca Comito
E-mail: comito.francesca@gmail.com

BACKGROUND

Pancreatic cancer is one of the most challenging human malignancies and ranks as the fourth leading cause of cancer-related mortality in the United States and Europe, with a 5-year survival rate of 7 to 8% among all disease stages. Surgery offers the only curative treatment for pancreatic cancer; however, in the large majority of cases, diagnosis is made at an advanced stage, when patients already have metastases or locoregional extension precluding curative surgical resection. Therapeutic options in this setting remain limited. During the past 5 years, two Phase III studies demonstrated that the FOLFIRINOX regimen (oxaliplatin, irinotecan, fluorouracil and leucovorin) and then the gemcitabine plus nab-paclitaxel regimen significantly improve survival in patients with metastatic adenocarcinoma of the pancreas. Both regimens are currently considered standards of care for first-line treatment in patients with advanced pancreatic cancer and good general condition [performance status (PS) Eastern Cooperative Oncology Group (ECOG) 0–1 for FOLFIRINOX and PS ECOG 0–2 for gemcitabine plus nab-paclitaxel].

Nab-paclitaxel (nanoparticle albumin-bound paclitaxel) is a solvent-free, albumin-coupled formulation of paclitaxel, indicated for the treatment of breast cancer, non-small cell lung cancer (NSCLC) and pancreatic cancer.

Gemcitabine is a pyrimidine antimetabolite and incorporates its active metabolite into the DNA, resulting in inhibition of DNA synthesis. It is used for the adjuvant and metastatic treatment of a wide variety of malignancies including breast, ovary, pancreas, bladder and NSCLC.

The most common adverse events of Grade 3 or higher, according to the Common Terminology Criteria for
Adverse Events (CTCAE) v4.0. gemcitabine and nab-paclitaxel combination are neutropenia, fatigue and neuropathy. The Phase 3 study MPACT reported significantly increased pneumonitis rates with the combination of gemcitabine and nab-paclitaxel compared to gemcitabine alone (4 vs 1%, respectively).

Here, we present a rare case of organizing pneumonia (OP) following long-term treatment with nab-paclitaxel and gemcitabine for metastatic pancreatic cancer.

CASE PRESENTATION
A Caucasian 68-year-old non-smoker female, without a significant medical history except for hypertension and family history of pancreatic cancer, underwent total splenopancreatectomy for ductal adenocarcinoma associated with branch-duct intraductal papillary mucinous neoplasm (BD-IPMN) of the neck of the pancreas. Since May to September 2014 she received adjuvant treatment in another hospital: 3 cycles of weekly gemcitabine (1000 mg m⁻²) followed by chemoradiation with gemcitabine (50.4 Gy in 28 fr). A thoracoabdominopelvic computer-assisted tomography (TAP-CT) performed in March 2015 showed the presence of cancer recurrence locally, in retroperitoneal lymph nodes and in lungs. A positron emission tomography with 18-fluoro-deoxyglucose was also performed in order to confirm the diagnosis of relapse. Since April 2015 the patient received first-line chemotherapy at our oncology department. We administered gemcitabine plus nab-paclitaxel combination (gemcitabine 1000 mg m⁻² and nab-paclitaxel 125 mg m⁻² on days 1, 8 and 15 every 4 weeks) for 12 cycles. The CT scans performed every two cycles showed stable disease, while a metabolic response was seen on positron emission tomography with 18-fluoro-deoxyglucose.

Following the administration of cycle 12, day 15 of gemcitabine plus nab-paclitaxel, the patient experienced low-grade pyrexia, effort dyspnoea, persistent non-productive cough and malaise. She was empirically treated with a 5-day course of levofloxacin as outpatient, without any beneficial effects, and for the worsening of the symptoms she was eventually hospitalized. On admission, blood examination revealed moderate anaemia (haemoglobin 9.3 g dl⁻¹) and an increased level of C-reactive protein (8.2 mg dl⁻¹), whereas white cell differential count, electrolytes and glucose levels and renal and liver function were within normal limits. A chest X-ray showed diffuse reduction of normal lung lucency, both perihilar and peripherical. High-resolution computed tomography (HRCT) scan showed new-onset bilateral peripheral ground-glass opacities, smooth interlobular septal thickening and patchy subpleural consolidation areas. These findings were consistent with OP (Figure 1).

Blood cultures were negative, as well as urine was negative for Legionella and Pneumococcal antigens. Serology tests for Mycoplasma, Legionella, cytomegalovirus, Epstein–Barr virus, adenovirus, influenza, parainfluenza and respiratory syncitial virus were negative, as was the Quantiferon-TB gold In-tube. The patient underwent bronchoscopy for bronchoalveolar lavage, and cytopathological and microbiological analyses were negative for infectious causes; the cell findings in bronchoalveolar lavage fluid were total cell count 271,000 ml⁻¹; macrophages 60%; lymphocytes 30%; neutrophils 10%; eosinophils 0%; no neoplastic cells. Chronic medications at diagnosis consisted in pancreatic enzyme supplements, insulin, amlodipine, pantoprazole and furosemide.

Suspecting chemotherapy-induced pneumonitis, nab-paclitaxel and gemcitabine were discontinued; the patient was started on treatment with prednisone 1 mg kg⁻¹ day⁻¹, which led to rapid clinical improvement. HRCT scan performed after 2 months showed disappearance of alveolar infiltrates and complete resolution of consolidation (Figure 2).

DISCUSSION
OP or bronchiolitis obliterans OP is a known manifestation of drug-induced lung injury. It is a histopathological reaction to a nonspecific inflammatory insult and can occur after exposure to a number of drugs including many antineoplastic agents.

Patients with OP typically present with a subacute illness of relatively short duration (median, less than 3 months) with low-grade fever and variable degrees of dyspnoea and non-productive cough. HRCT characteristically shows patchy and often migratory consolidation in a subpleural, peribronchial or band-like pattern, commonly associated with ground-glass opacities. Perilobular opacities and reversed halo sign may be helpful in
suggesting the diagnosis. In 10–30% of patients, small unilateral or bilateral pleural effusion may occur. The radiographic differential diagnosis of OP includes alveolar cell carcinoma, lymphoma, vasculitis, sarcoidosis and infection (particularly tuberculosis or atypical mycobacterial infection). When the consolidation is subpleural, the diagnosis of chronic eosinophilic pneumonia should also be considered.

The pathology of OP is inflammatory fibrin filling the alveoli and spreading to the alveolar ducts and terminal bronchioles, with peculiar endoluminal buds of granulation tissue; an interstitial inflammatory infiltrate can be associated with these abnormalities. However, histological diagnosis, in the same way as in other interstitial lung disease, is no longer deemed to be the gold standard. Analysis of all available data in a multidisciplinary meeting should be performed in order to define the settings where biopsy is more informative than HRCT and those where biopsy is not needed.

The majority of patients recover completely with oral corticosteroids, with the symptoms resolving within days or weeks. However, sporadic reports have identified a subgroup of patients with OP that does not completely resolve in spite of prolonged treatment. Some of these cases show residual or progressive interstitial fibrosis, often with recurrent episodes of OP.

Some cases of gemcitabine-induced OP have been reported to date (Table 1). Among those, two patients received single-agent gemcitabine treatment for pancreatic cancer, while the other three cases describe OP occurring in patients affected by lung cancer receiving a gemcitabine-containing doublet chemotherapy. A case of OP has also been described in a patient on treatment with trastuzumab and nab-paclitaxel for metastatic breast cancer, as well as fatal interstitial pneumonitis in a patient with refractory small cell lung cancer after two cycles of single-agent nab-paclitaxel.

Gemcitabine is generally a well-tolerated chemotherapeutic agent; however, a wide spectrum of lung toxicities have been reported with its use. Gemcitabine-related pneumonitis has been documented in patients with varied cancers in sites such as lung, ovary, breast, gallbladder and pancreas and is a potentially fatal complication that may cause significant morbidity and, rarely, mortality. The incidence of gemcitabine-induced...

| References         | Primary diagnosis | Chemotherapeutic agents | Treatment (type and dosage)                     | Outcomes                                    |
|--------------------|-------------------|-------------------------|------------------------------------------------|---------------------------------------------|
| Shaib et al11      | Pancreatic cancer | Gemcitabine alone       | Steroids (not reported)                         | Clinical and CT improvement                |
| Kawsar et al12     | Non-small cell lung cancer | Carboplatin, gemcitabine | Steroids (not reported)                         | Clinical and CT improvement                |
| Cobo Dols et al13  | Non-small cell lung cancer | Docetaxel, gemcitabine  | Steroids (methylprednisone, 160 mg day⁻¹)     | Clinical and CT improvement                |
| Aguiar Bujanda D et al14 | Non-small cell lung cancer | Paclitaxel, carboplatin, gemcitabine | Steroids (not reported) | Rapid clinical improvement within 24 h and chest X-ray improvement after 3 weeks |
| Hiraya et al15     | Pancreatic cancer | Gemcitabine alone       | Steroids (methylprednisone 300 mg day⁻¹ for 3 days and afterwards tapered off) | Rapid clinical improvement and CT improvement after 3 weeks |

Table I. Reports of gemcitabine organizing pneumonia

Figure 2. (a) Coronal and (b) axial images from thorax CT performed after 2 months of steroid treatment. Complete resolution of the diffuse and bilateral ground-glass opacities and of the consolidation areas, with an increase in the size of the nodules, known as lung metastases.
Pneumonitis has been reported in different studies at rates ranging from 0.06 to 2.15%, and several clinical trials report a higher rate of pneumonitis in treatment that combines gemcitabine with other agents such as nab-paclitaxel and erlotinib.

Paclitaxel is also known to cause pneumonitis with an incidence ranging from 1 to 4%, increasing when paclitaxel is combined with other cytotoxic drugs or radiation therapy.

When considering risk factors of pulmonary toxicity one might hypothesize that combination chemotherapy, pre-existing pulmonary disease such as pulmonary metastatic disease and prior or concurrent radiation therapy play a role.

Regarding our patient’s risk factors, she did have pulmonary metastases and received combination chemotherapy.

Patients receiving antineoplastic treatment who develop new respiratory symptoms or have abnormal chest radiographs are frequently encountered. Typically, the first concern is either progressive disease or an infectious process. These conditions are not easily differentiated on the basis of clinical presentation and radiographic findings. Moreover, as patients usually receive multiple antineoplastic agents, it is usually problematic to identify the culprit agent. Regardless of these difficulties, clinicians should consider this diagnosis when evaluating a patient receiving chemotherapeutic agents with a new pulmonary process. Discontinuation of the implicated causative agent and treatment with systemic corticosteroids may result in an excellent outcome.

To our knowledge, this is a rare case report of OP in a patient treated with gemcitabine and nab-paclitaxel for pancreatic cancer. This case report highlights the necessity of a high level of alertness for emerging respiratory symptoms for early intervention and management of a potential diagnosis of pneumonitis during gemcitabine and nab-paclitaxel therapy, which is now a commonly used first-line standard therapy for patients with metastatic pancreatic adenocarcinoma.

**LEARNING POINTS**

1. OP is a distinct disorder of lungs that can clinically present with subacute illness with low-grade fever and variable degrees of non-productive cough and dyspnoea.
2. OP diagnosis is mainly radiological. HRCT shows patchy and often migratory consolidation in a subpleural, peribronchial, or band-like pattern, commonly associated with ground-glass opacity.
3. OP is a rare, but possible consequence of treatment with nab-paclitaxel and gemcitabine. To confirm an association between a drug and OP, other causes, especially infectious, must be ruled out.
4. Once the diagnosis of OP is confirmed, early intervention including withdrawal of the chemotherapeutic agent and prompt use of corticosteroids is recommended.

**CONSENT**

Written informed consent for the case to be published (including images, case history and data) was obtained from the patient(s) for publication of this case report, including accompanying images.

**REFERENCES**

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11–30. doi: https://doi.org/10.3322/caac.21166
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374–403. doi: https://doi.org/10.1016/j.ejca.2012.12.027
3. American Cancer Society. Cancer facts & figures 2016. 2016. Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf [Accessed 1 May 2017]
4. National Cancer Institute. SEER Stat Fact Sheets: pancreatic cancer. Available from: http://seer.cancer.gov/statfacts/html/pancreas.html [Accessed 1 May 2017]
5. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014; 371: 1039–49. doi: https://doi.org/10.1056/NEJMra1404198
6. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–25. doi: https://doi.org/10.1056/NEJMoa1011923
7. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691–703. doi: https://doi.org/10.1056/NEJMoa1304369
8. Epler GR. Bronchiolitis obliterans organizing pneumonia, 25 years: a variety of causes, but what are the treatment options? Expert Rev Respir Med 2011; 5: 353–61. doi: https://doi.org/10.1586/ers.11.19
9. Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. An official American thoracic society/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–48.
10. Travis WD, King TE, Bateman ED, Lynch DA, Capron F, Center D, et al. American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277–304.
11. Shahb W, Lansigan F, Cornfeld D, Syrigos K, Saif MW. Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP 2008; 9: 708–14.
12. Kawasaki HI, Spiro TP, Cocco A, Daw HA. BOOP as a rare complication of gemcitabine therapy. BMJ Case Rep 2011; 2011: bcr0420114055. doi: https://doi.org/10.1136/bcr.04.2011.4055
13. Cobo Dols M, Gil Calle S, Álvez Díaz I, Villar Chamorro E, Alcaide García J, Gutiérrez Calderón V, et al. Bronchiolitis obliterans organizing pneumonia simulating progression in bronchoalveolar carcinoma. Clin Transl Oncol 2006; 8: 133–5.
do: https://doi.org/10.1007/s12094-006-0171-0
14. Aguiar Bujanda D, Aguiar Morales J, Bohn Sarmiento U. Bronchiolitis obliterans organizing pneumonia induced by chemotherapy. *Arch Bronconeumol* 2004; 40: 290.
15. Hiraya D, Kagohashi K, Sakamoto N, Kondo T, Satoh H. Gemcitabine-induced pulmonary toxicity in a patient with pancreatic cancer. *JOP* 2010; 11: 186–8.
16. Gupta A, Teo L, Masel P, Goodbolt D, Beadle G. Transstuzumab induced organizing pneumonia: a case report. *Springerplus* 2016; 5: 1964. doi: https://doi.org/10.1186/s40064-016-3647-6
17. Wang B, Yang J, Luo D, Qiao H, Xie Z, Zhang X, et al. Complete remission and fatal interstitial pneumonitis related to nab-paclitaxel in refractory small cell lung cancer: a case report and review of the literature. *Thorac Cancer* 2012; 3: 84–7. doi: https://doi.org/10.1111/j.1759-7714.2011.00086.x
18. Chi DC, Brogan F, Turenne I, Zelonis S, Schwartz L, Saif MW. Gemcitabine-induced pulmonary toxicity. *Anticancer Res* 2012; 32: 4147–9.
19. Gupta N, Ahmed I, Steinberg H, Patel D, Nisel-Horowitz S, Mehrotra B. Gemcitabine-induced pulmonary toxicity: case report and review of the literature. *Am J Clin Oncol* 2002; 25: 96–100.
20. Galvão FH, Pestana JO, Capelozzi VL. Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma. *Cancer Chemother Pharmacol* 2010; 65: 607–10. doi: https://doi.org/10.1007/s00280-009-1167-6
21. Rosado MF, Kett DH, Schein RM, Baraona FJ, Sridhar KS. Severe pulmonary toxicity in a patient treated with gemcitabine. *Am J Clin Oncol* 2002; 25: 31–3. doi: https://doi.org/10.1097/00000421-200202000-00005
22. Dunsford ML, Mead GM, Bateman AC, Cook T, Tung K. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. *Ann Oncol* 1999; 10: 943–7. doi: https://doi.org/10.1032/A:1008377819875
23. Roychowdhury DF, Cassidy CA, Peterson P, Arning M. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. *Invest New Drugs* 2002; 20: 311–5. doi: https://doi.org/10.1023/A:1016214032272
24. Hamada T, Yasunaga H, Nakay Y, Isayama H, Matsui H, Fushimi K, et al. Interstitial lung disease associated with gemcitabine: a Japanese retrospective cohort study. *Respirology* 2016; 21: 338–43. doi: https://doi.org/10.1111/resp.12665
25. Moore MJ, Goldstein D, Hamm J, Figuer A, Hecht JR, Gallinger S, et al. National Cancer Institute of Canada Clinical Trials Group Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. *J Clin Oncol* 2007; 25: 1960–6. doi: https://doi.org/10.1200/JCO.2006.07.9525
26. Goldberg HL, Vannice SB. Pneumonitis related to treatment with paclitaxel. *J Clin Oncol* 1995; 13: 534–5. doi: https://doi.org/10.1200/JCO.1995.13.2.534
27. Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. *Chest* 2008; 133: 328–38. doi: https://doi.org/10.1378/chest.07-0851